SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (5970)3/20/2002 10:42:28 AM
From: Biomaven  Read Replies (2) | Respond to of 52153
 
patients lived longer because the starved tumors were unable to replicate

Well the FDA isn't exactly going to have a problem with using death as an endpoint instead of a surrogate measure like tumor shrinkage. <g>

But of course it does mean that trials would take that much longer (which of course is mainly why companies have always pushed for the use of surrogate endpoints instead).

Peter



To: aknahow who wrote (5970)3/20/2002 3:49:35 PM
From: LLCF  Read Replies (1) | Respond to of 52153
 
Thanks... interesting. Isn't anti-angiogenesis also becoming 'crowded'???

DAK


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News